List view / Grid view
Researchers have discovered a breakthrough method to silence MRSA's drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs.
ElevateBio is teaming up with Amazon Web Services (AWS) to advance CRISPR gene editing using AI and cloud computing. This collaboration aims to accelerate drug discovery for genetic diseases, making next-generation therapies more efficient and accessible.
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
York University researchers have discovered a genetic mutation in the TRAF1 protein that dramatically reduces inflammation, offering a potential breakthrough in rheumatoid arthritis treatment.
Researchers have identified a small gene, SCN10a-short, that could enable gene therapy to treat malignant cardiac arrhythmias. This discovery offers the potential for a one-time treatment, reducing the reliance on lifelong medication and invasive procedures.
A new study has identified novel drug targets for heart failure, focusing on two major types of the condition. These findings could lead to more effective, targeted treatments for both heart failure subtypes.
CTMC, a joint venture between Resilience + MD Anderson Cancer Center, is transforming cancer treatment with faster, more efficient cell therapy development - learn how they’re doing it.
New study reveals that TLE6 protein deficiency causes male infertility in mice. These findings suggest potential genetic causes and future treatment avenues for male infertility.
The human body has an incredible ability to repair itself, both from acute trauma and chronic damage that accumulates as we age. Here, Cameron Lee, Principal Scientist at Tune Therapeutics, reveals the potential of harnessing the body’s natural regenerative capabilities with epigenetic control of stem cells.
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
The study’s findings could contribute to future therapeutic strategies to prevent chronic kidney disease.
Mice with rod-specific VPS35 deletion demonstrate a pathology more similar to human Parkinson’s disease, compared to other mouse models.
